Fineline Cube

Follow:
14409 Articles
Jiangsu Hengrui Pharmaceuticals' Fluzoparib and Apatinib Gain NMPA Approval for Metastatic Breast Cancer Treatment
CompanyDeals

Jiangsu Hengrui Pharmaceuticals’ Fluzoparib and Apatinib Gain NMPA Approval for Metastatic Breast Cancer Treatment

Explore the latest insights on Fangzhou and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Fangzhou's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.
CompanyDeals

Fangzhou Inc. Expands Partnerships with Tencent Healthcare and Baidu Health at Digital Summit

MGI Tech Co., Ltd Partners with Universidad de San Martín de Porre for Genomic Sequencing Advancement
CompanyDeals

MGI Tech Co., Ltd Partners with Universidad de San Martín de Porre for Genomic Sequencing Advancement

VFLO Medical Partners with Inari Medical to Expand Access in Greater China
CompanyDeals

VFLO Medical Partners with Inari Medical to Expand Access in Greater China

Uni-Bio Science Group Achieves Milestones in Medical Aesthetics with New Product Approvals
CompanyDrug

Uni-Bio Science Group Achieves Milestones in Medical Aesthetics with New Product Approvals

Ocumen Therapeutics' OT-301 Phase III Denali Study Surpasses 140 Patient Enrollment in China
CompanyDrug

Ocumen Therapeutics’ OT-301 Phase III Denali Study Surpasses 140 Patient Enrollment in China

China Medical System Holdings Secures Exclusive Rights to Atom Therapeutics' Gout Drug ABP-671
CompanyDeals

China Medical System Holdings Secures Exclusive Rights to Atom Therapeutics’ Gout Drug ABP-671

Novartis Secures Global Rights to PTC Therapeutics' Huntington's Disease Treatment PTC518
CompanyDeals

Novartis Secures Global Rights to PTC Therapeutics’ Huntington’s Disease Treatment PTC518

UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China
CompanyDeals

UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China

Minghui Pharmaceutical's MH004 Ointment Meets Primary Endpoints in Atopic Dermatitis Phase III Study
CompanyDrug

Minghui Pharmaceutical’s MH004 Ointment Meets Primary Endpoints in Atopic Dermatitis Phase III Study

China's NHC Launches Pilot Plan to Expand Wholly Foreign-Owned Hospital Sector
Policy / Regulatory

China’s NHC Launches Pilot Plan to Expand Wholly Foreign-Owned Hospital Sector

Hua Medicine's Second-Generation GKA HM-002-1005 Completes Phase Ia Study in the US
CompanyDrug

Hua Medicine’s Second-Generation GKA HM-002-1005 Completes Phase Ia Study in the US